The pharmacokinetic diversity of two von willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von willebrand disease: Results from a prospective, randomised crossover study

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 279-288

  Kessler, Craig M ^a   Friedman, Ken ^b   Schwartz, Bruce A ^c   Gill, Joan C ^b   Powell, Jerry S ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c Octapharma USA Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Factor VIII von willebrand factor concentrate; Humate p ; Pharmacokinetics; Ristocetin co factor; Wilate

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN MULTIMERIZATION; THERAPEUTIC EQUIVALENCY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 79961073761     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-02-0057     Document Type: Article

References (24)

1. Sugimoto M, Miyata S. Functional property of von Willebrand factor under flowing blood. Int J Hematol 2002; 75: 19-24.
2. Mannucci PM. Treatment of von Willebrand's disease. New Engl J Med 2004; 351: 683-694.
3. Saenko EL, Ananyeva NM, Tuddenbaum EG, et al. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119: 323-331.
4. Federici AB, Castaman G, Thompson A, et al. Von Willebrand's disease: clinical management. Haemophilia 2006; 12 (Suppl 3): 152-158.
5. Ingerslev J, Hvitfeldt PL, Sorensen B. Current treatment of von Willebrand's disease. Hamostaseologie 2004; 24: 56-64.
6. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence- based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
7. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34: 281-288.
8. Strandberg K, Lethagen S, Andersson K, et al. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost 2006; 12: 61-67.
9. Hillarp A, Stadler M, Haderer C, et al. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8: 2216-2223.
10. Barrowcliffe TW, Raut S, Sands D, et al. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-256.
11. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001; 113: 533-536.
12. Budde U, Schneppenheim R, Plendl H, et al. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-315.
13. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (Suppl 3): 33-39.
14. Lethagen S, Kyrle PA, Castaman G, et al. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-1430.
15. Berntorp E, Windyga A, European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-130.
16. Berntorp E. Haemate P/Humate-P: a Systematic review. Thromb Res 2009; 124 (Suppl 1): S11-14.
17. Auerswald G, Kreuz W. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. Haemophilia 2008; 14 (Suppl 5): 39-46.
18. Favaloro EJ, Lloyd J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF(High Purity)] in people with von Willebrand disorder-A randomized cross-over, multi-centre study. Thromb Haemost 2007; 97: 922-930.
19. Fuchs B, Solecka B, Kroening M, et al. Does the von Willebrand factor (VWF) triplet structure affect VWF function? Haemophilia 2010; 16 (Suppl 4): 1-158.
20. Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-456.
21. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
22. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
23. Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-388.
24. Windyga J, von Depka-Prondzinski M. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-1079.